Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Вирус папилломы человека: этиология, патогенез, роль и значение в развитии рака шейки матки
Вирус папилломы человека: этиология, патогенез, роль и значение в развитии рака шейки матки
Зиганшин А.М., Кейдар С.В., Халитова Р.Ш., Мулюков А.Р., Мухамедьярова Э.Н. Вирус папилломы человека: этиология, патогенез, роль и значение в развитии рака шейки матки. Гинекология. 2023;25(1):17–21.
DOI: 10.26442/20795696.2023.1.202070
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/20795696.2023.1.202070
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Вирус папилломы человека (ВПЧ) в наши дни считается самой распространенной инфекцией, передающейся половым путем. С момента открытия Нобелевским лауреатом Харальдом цур Хаузеном (2008 г.) ВПЧ как вируса, обладающего высоким канцерогенным риском, кардинально изменилась стратегия скрининга и профилактики данного заболевания. Все это значительно повысило актуальность исследования данной инфекции. Хотя ВПЧ не является угрожающим жизни человека, существующие высокоонкогенные подтипы способны приводить к развитию рака шейки матки и патологии, характеризующейся высокой летальностью.
Ключевые слова: вирус папилломы человека, рак шейки матки, вакцинация, иммунизация, дисплазия, Гардасил, Церварикс
Keywords: human papillomavirus, cervical cancer, cervical intraepithelial neoplasia, Cervarix, Gardasil, Gardasil 9
Ключевые слова: вирус папилломы человека, рак шейки матки, вакцинация, иммунизация, дисплазия, Гардасил, Церварикс
________________________________________________
Keywords: human papillomavirus, cervical cancer, cervical intraepithelial neoplasia, Cervarix, Gardasil, Gardasil 9
Полный текст
Список литературы
1. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. American Cancer Society Guideline Development Group. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016;66(5):375-85. DOI:10.3322/caac.21355
2. Краснопольский В.И., Зароченцева Н.В., Микаелян А.В., и др. Роль папилломавирусной инфекции в патологии беременности и исходе для новорожденного (современные представления). Российский вестник акушера-гинеколога. 2016;16(2):30‑6 [Krasnopol'skii VI, Zarochentseva NV, Mikaelian AV, et al. Role of papillomavirus infection in pregnancy pathology and outcome for the newborn: Current ideas. Russian Bulletin of Obstetrician-Gynecologist. 2016;16(2):30-6 (in Russian)].
3. Pastrana DV, Peretti A, Welch NL, et al. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. mSphere. 2018;3(6):e00645-18. DOI:10.1128/mSphereDirect.00645-18
4. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602-8. DOI:10.1080/01443615.2019.1634030
5. Прилепская В.Н. ВПЧ-ассоциированные заболевания шейки матки: скрининг, методы обследования, принципы лечения. Гинекология. 2019;21(3):6-8 [Prilepskaya VN. HPV-associated cervical diseases: screening, methods of examination, principles of treatment. Gynecology. 2019;21(3):6-8 (in Russian)].
6. Принципы диагностики, терапии и профилактики гинекологической патологии, ассоциированной с папилломавирусной инфекцией. Под ред. А.Г. Ящук, Р.М. Зайнуллина, А.В. Масленникова, и др. М.: Первая типография, 2018; c. 84 [Printsipy diagnostiki, terapii i profilaktiki ginekologicheskoi patologii, assotsiirovannoi s papillomavirusnoi infektsiiei. Pod red. AG Iashchuk, RM Zainullina, AV Maslennikova, et al. Moscow: Pervaia tipografiia, 2018; p. 84 (in Russian)].
7. Зиганшин А.М., Мулюков А.Р. Механизмы иммунопатологии сепсиса вирусной этиологии при COVID-19. Сибирское медицинское обозрение. 2021;6:35-43 [Ziganshin AM, Mulykov AR. Immunopathological mechanisms in sepsis of viral etiology in COVID-19. Siberian Medical Review. 2021;6:35-43 (in Russian)]. DOI:10.20333/25000136-2021-6-35-43
8. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res: Clin Obstet Gynaecol. 2018;47:14-26. DOI:10.1016/j.bpobgyn.2017.08.006
9. Keiffer TR, Soorya S, Sapp MJ. Recent Advances in Our Understanding of the Infectious Entry Pathway of Human Papillomavirus Type 16. Microorganisms. 2021;9(10):2076. DOI:10.3390/microorganisms9102076
10. Huber B, Schellenbacher C, Shafti-Keramat S, et al. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One. 2017;12(1):e0169533. DOI:10.1371/journal.pone.0169533
11. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864-78. DOI:10.20892/j.issn.2095-3941.2020.0370
12. Tekalegn Y, Sahiledengle B, Woldeyohannes D, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Womens Health (London). 2022;18:17455065221075904. DOI:10.1177/17455065221075904
13. Sadri Nahand J, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer. 2020;146(2):305-20. DOI:10.1002/ijc.32688
14. Barr AR, Cooper S, Heldt FS, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8:14728. DOI:10.1038/ncomms14728
15. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10:3116. DOI:10.3389/fmicb.2019.03116
16. Короленкова Л.И., Завольская Ж.А., Лешкина Г.В. Новые возможности молекулярного тестирования в цервикальном скрининге и ранней диагностике предрака и рака шейки матки (по материалам клинических рекомендаций «Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки» Минздрава России от 2020 г.). Медицинский оппонент. 2020;3(11):12-8 [Korolenkova LI, Zavolskaya ZHA, Leshkina GV. New opportunities of molecular testing in cervical screening and early diagnosis of cin and cervical cancer (based on the 2020 clinical guidelines of the RF Ministry of Healthcare “Cervical intraepithelial neoplasia, erosion and ectropion“). Medical Opponent. 2020;3(11):12-8 (in Russian)].
17. Kojima Y, Otsuki N, Kubo M, et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells. Cancer Gene Ther. 2018;25(9-10):274-83. DOI:10.1038/s41417-018-0024-3
18. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203. DOI:10.1016/S2214-109X(19)30482-6
19. Zhen S, Lu J, Liu YH, et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout. Cancer Gene Ther. 2020;27(3-4):168-78. DOI:10.1038/s41417-019-0131-9
20. Bienvenu E, Mukanyangezi MF, Rulisa S, et al. Changes in the Proteome in the Development of Chronic Human Papillomavirus Infection-A Prospective Study in HIV Positive and HIV Negative Rwandan Women. Cancers (Basel). 2021;13(23):5983. DOI:10.3390/cancers13235983
21. Smalley Rumfield C, Pellom ST, Morillon Ii YM, et al. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer. 2020;8(1):e000612. DOI:10.1136/jitc-2020-000612
22. Sundström K, Elfström KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med. 2020;17(1):e1003035. DOI:10.1371/journal.pmed.1003035
23. Schlecht NF, Masika M, Diaz A, et al. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Network Open. 2019;2(10):e1914031. DOI:10.1001/jamanetworkopen.2019.14031
24. Saadeh K, Park I, Gargano JW, et al. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2020;38(1):39-45. DOI:10.1016/j.vaccine.2019.09.103
25. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020;172(1):22-9. DOI:10.7326/M19-1182
26. Sonawane K, Suk R, Chiao EY, et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167(10):714-24. DOI:10.7326/M17-1363
27. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020;8(3):391. DOI:10.3390/vaccines8030391
28. Huber B, Wang JW, Roden RBS, Kirnbauer R. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. J Clin Med. 2021;10(5):1044. DOI:10.3390/jcm10051044
29. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9(12):1413. DOI:10.3390/vaccines9121413
30. Rosalik K, Tarney C, Han J. Human Papilloma Virus Vaccination. Viruses. 2021;13(6):1091. DOI:10.3390/v13061091
31. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. DOI:10.1093/cid/ciy274
32. Markowitz LE, Drolet M, Perez N, et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018;36(32 Pt A):4806-15. DOI:10.1016/j.vaccine.2018.01.057
33. Barnabas RV, Brown ER, Onono M, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials. 2021;22(1):661. DOI:10.1186/s13063-021-05608-8
34. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-90. DOI:10.1016/S0140-6736(20)30068-4
2. Krasnopol'skii VI, Zarochentseva NV, Mikaelian AV, et al. Role of papillomavirus infection in pregnancy pathology and outcome for the newborn: Current ideas. Russian Bulletin of Obstetrician-Gynecologist. 2016;16(2):30-6 (in Russian).
3. Pastrana DV, Peretti A, Welch NL, et al. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. mSphere. 2018;3(6):e00645-18. DOI:10.1128/mSphereDirect.00645-18
4. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602-8. DOI:10.1080/01443615.2019.1634030
5. Prilepskaya VN. HPV-associated cervical diseases: screening, methods of examination, principles of treatment. Gynecology. 2019;21(3):6-8 (in Russian).
6. Printsipy diagnostiki, terapii i profilaktiki ginekologicheskoi patologii, assotsiirovannoi s papillomavirusnoi infektsiiei. Pod red. AG Iashchuk, RM Zainullina, AV Maslennikova, et al. Moscow: Pervaia tipografiia, 2018; p. 84 (in Russian).
7. Ziganshin AM, Mulykov AR. Immunopathological mechanisms in sepsis of viral etiology in COVID-19. Siberian Medical Review. 2021;6:35-43 (in Russian).
DOI:10.20333/25000136-2021-6-35-43
8. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res: Clin Obstet Gynaecol. 2018;47:14-26. DOI:10.1016/j.bpobgyn.2017.08.006
9. Keiffer TR, Soorya S, Sapp MJ. Recent Advances in Our Understanding of the Infectious Entry Pathway of Human Papillomavirus Type 16. Microorganisms. 2021;9(10):2076. DOI:10.3390/microorganisms9102076
10. Huber B, Schellenbacher C, Shafti-Keramat S, et al. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One. 2017;12(1):e0169533. DOI:10.1371/journal.pone.0169533
11. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864-78. DOI:10.20892/j.issn.2095-3941.2020.0370
12. Tekalegn Y, Sahiledengle B, Woldeyohannes D, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Womens Health (London). 2022;18:17455065221075904. DOI:10.1177/17455065221075904
13. Sadri Nahand J, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer. 2020;146(2):305-20. DOI:10.1002/ijc.32688
14. Barr AR, Cooper S, Heldt FS, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8:14728. DOI:10.1038/ncomms14728
15. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10:3116. DOI:10.3389/fmicb.2019.03116
16. Korolenkova LI, Zavolskaya ZHA, Leshkina GV. New opportunities of molecular testing in cervical screening and early diagnosis of cin and cervical cancer (based on the 2020 clinical guidelines of the RF Ministry of Healthcare “Cervical intraepithelial neoplasia, erosion and ectropion“). Medical Opponent. 2020;3(11):12-8 (in Russian).
17. Kojima Y, Otsuki N, Kubo M, et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells. Cancer Gene Ther. 2018;25(9-10):274-83. DOI:10.1038/s41417-018-0024-3
18. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203. DOI:10.1016/S2214-109X(19)30482-6
19. Zhen S, Lu J, Liu YH, et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout. Cancer Gene Ther. 2020;27(3-4):168-78. DOI:10.1038/s41417-019-0131-9
20. Bienvenu E, Mukanyangezi MF, Rulisa S, et al. Changes in the Proteome in the Development of Chronic Human Papillomavirus Infection-A Prospective Study in HIV Positive and HIV Negative Rwandan Women. Cancers (Basel). 2021;13(23):5983. DOI:10.3390/cancers13235983
21. Smalley Rumfield C, Pellom ST, Morillon Ii YM, et al. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer. 2020;8(1):e000612. DOI:10.1136/jitc-2020-000612
22. Sundström K, Elfström KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med. 2020;17(1):e1003035. DOI:10.1371/journal.pmed.1003035
23. Schlecht NF, Masika M, Diaz A, et al. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Network Open. 2019;2(10):e1914031. DOI:10.1001/jamanetworkopen.2019.14031
24. Saadeh K, Park I, Gargano JW, et al. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2020;38(1):39-45. DOI:10.1016/j.vaccine.2019.09.103
25. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020;172(1):22-9. DOI:10.7326/M19-1182
26. Sonawane K, Suk R, Chiao EY, et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167(10):714-24. DOI:10.7326/M17-1363
27. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020;8(3):391. DOI:10.3390/vaccines8030391
28. Huber B, Wang JW, Roden RBS, Kirnbauer R. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. J Clin Med. 2021;10(5):1044. DOI:10.3390/jcm10051044
29. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9(12):1413. DOI:10.3390/vaccines9121413
30. Rosalik K, Tarney C, Han J. Human Papilloma Virus Vaccination. Viruses. 2021;13(6):1091. DOI:10.3390/v13061091
31. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. DOI:10.1093/cid/ciy274
32. Markowitz LE, Drolet M, Perez N, et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018;36(32 Pt A):4806-15. DOI:10.1016/j.vaccine.2018.01.057
33. Barnabas RV, Brown ER, Onono M, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials. 2021;22(1):661. DOI:10.1186/s13063-021-05608-8
34. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-90. DOI:10.1016/S0140-6736(20)30068-4
2. Краснопольский В.И., Зароченцева Н.В., Микаелян А.В., и др. Роль папилломавирусной инфекции в патологии беременности и исходе для новорожденного (современные представления). Российский вестник акушера-гинеколога. 2016;16(2):30‑6 [Krasnopol'skii VI, Zarochentseva NV, Mikaelian AV, et al. Role of papillomavirus infection in pregnancy pathology and outcome for the newborn: Current ideas. Russian Bulletin of Obstetrician-Gynecologist. 2016;16(2):30-6 (in Russian)].
3. Pastrana DV, Peretti A, Welch NL, et al. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. mSphere. 2018;3(6):e00645-18. DOI:10.1128/mSphereDirect.00645-18
4. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602-8. DOI:10.1080/01443615.2019.1634030
5. Прилепская В.Н. ВПЧ-ассоциированные заболевания шейки матки: скрининг, методы обследования, принципы лечения. Гинекология. 2019;21(3):6-8 [Prilepskaya VN. HPV-associated cervical diseases: screening, methods of examination, principles of treatment. Gynecology. 2019;21(3):6-8 (in Russian)].
6. Принципы диагностики, терапии и профилактики гинекологической патологии, ассоциированной с папилломавирусной инфекцией. Под ред. А.Г. Ящук, Р.М. Зайнуллина, А.В. Масленникова, и др. М.: Первая типография, 2018; c. 84 [Printsipy diagnostiki, terapii i profilaktiki ginekologicheskoi patologii, assotsiirovannoi s papillomavirusnoi infektsiiei. Pod red. AG Iashchuk, RM Zainullina, AV Maslennikova, et al. Moscow: Pervaia tipografiia, 2018; p. 84 (in Russian)].
7. Зиганшин А.М., Мулюков А.Р. Механизмы иммунопатологии сепсиса вирусной этиологии при COVID-19. Сибирское медицинское обозрение. 2021;6:35-43 [Ziganshin AM, Mulykov AR. Immunopathological mechanisms in sepsis of viral etiology in COVID-19. Siberian Medical Review. 2021;6:35-43 (in Russian)]. DOI:10.20333/25000136-2021-6-35-43
8. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res: Clin Obstet Gynaecol. 2018;47:14-26. DOI:10.1016/j.bpobgyn.2017.08.006
9. Keiffer TR, Soorya S, Sapp MJ. Recent Advances in Our Understanding of the Infectious Entry Pathway of Human Papillomavirus Type 16. Microorganisms. 2021;9(10):2076. DOI:10.3390/microorganisms9102076
10. Huber B, Schellenbacher C, Shafti-Keramat S, et al. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One. 2017;12(1):e0169533. DOI:10.1371/journal.pone.0169533
11. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864-78. DOI:10.20892/j.issn.2095-3941.2020.0370
12. Tekalegn Y, Sahiledengle B, Woldeyohannes D, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Womens Health (London). 2022;18:17455065221075904. DOI:10.1177/17455065221075904
13. Sadri Nahand J, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer. 2020;146(2):305-20. DOI:10.1002/ijc.32688
14. Barr AR, Cooper S, Heldt FS, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8:14728. DOI:10.1038/ncomms14728
15. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10:3116. DOI:10.3389/fmicb.2019.03116
16. Короленкова Л.И., Завольская Ж.А., Лешкина Г.В. Новые возможности молекулярного тестирования в цервикальном скрининге и ранней диагностике предрака и рака шейки матки (по материалам клинических рекомендаций «Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки» Минздрава России от 2020 г.). Медицинский оппонент. 2020;3(11):12-8 [Korolenkova LI, Zavolskaya ZHA, Leshkina GV. New opportunities of molecular testing in cervical screening and early diagnosis of cin and cervical cancer (based on the 2020 clinical guidelines of the RF Ministry of Healthcare “Cervical intraepithelial neoplasia, erosion and ectropion“). Medical Opponent. 2020;3(11):12-8 (in Russian)].
17. Kojima Y, Otsuki N, Kubo M, et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells. Cancer Gene Ther. 2018;25(9-10):274-83. DOI:10.1038/s41417-018-0024-3
18. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203. DOI:10.1016/S2214-109X(19)30482-6
19. Zhen S, Lu J, Liu YH, et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout. Cancer Gene Ther. 2020;27(3-4):168-78. DOI:10.1038/s41417-019-0131-9
20. Bienvenu E, Mukanyangezi MF, Rulisa S, et al. Changes in the Proteome in the Development of Chronic Human Papillomavirus Infection-A Prospective Study in HIV Positive and HIV Negative Rwandan Women. Cancers (Basel). 2021;13(23):5983. DOI:10.3390/cancers13235983
21. Smalley Rumfield C, Pellom ST, Morillon Ii YM, et al. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer. 2020;8(1):e000612. DOI:10.1136/jitc-2020-000612
22. Sundström K, Elfström KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med. 2020;17(1):e1003035. DOI:10.1371/journal.pmed.1003035
23. Schlecht NF, Masika M, Diaz A, et al. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Network Open. 2019;2(10):e1914031. DOI:10.1001/jamanetworkopen.2019.14031
24. Saadeh K, Park I, Gargano JW, et al. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2020;38(1):39-45. DOI:10.1016/j.vaccine.2019.09.103
25. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020;172(1):22-9. DOI:10.7326/M19-1182
26. Sonawane K, Suk R, Chiao EY, et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167(10):714-24. DOI:10.7326/M17-1363
27. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020;8(3):391. DOI:10.3390/vaccines8030391
28. Huber B, Wang JW, Roden RBS, Kirnbauer R. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. J Clin Med. 2021;10(5):1044. DOI:10.3390/jcm10051044
29. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9(12):1413. DOI:10.3390/vaccines9121413
30. Rosalik K, Tarney C, Han J. Human Papilloma Virus Vaccination. Viruses. 2021;13(6):1091. DOI:10.3390/v13061091
31. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. DOI:10.1093/cid/ciy274
32. Markowitz LE, Drolet M, Perez N, et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018;36(32 Pt A):4806-15. DOI:10.1016/j.vaccine.2018.01.057
33. Barnabas RV, Brown ER, Onono M, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials. 2021;22(1):661. DOI:10.1186/s13063-021-05608-8
34. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-90. DOI:10.1016/S0140-6736(20)30068-4
________________________________________________
2. Krasnopol'skii VI, Zarochentseva NV, Mikaelian AV, et al. Role of papillomavirus infection in pregnancy pathology and outcome for the newborn: Current ideas. Russian Bulletin of Obstetrician-Gynecologist. 2016;16(2):30-6 (in Russian).
3. Pastrana DV, Peretti A, Welch NL, et al. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. mSphere. 2018;3(6):e00645-18. DOI:10.1128/mSphereDirect.00645-18
4. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602-8. DOI:10.1080/01443615.2019.1634030
5. Prilepskaya VN. HPV-associated cervical diseases: screening, methods of examination, principles of treatment. Gynecology. 2019;21(3):6-8 (in Russian).
6. Printsipy diagnostiki, terapii i profilaktiki ginekologicheskoi patologii, assotsiirovannoi s papillomavirusnoi infektsiiei. Pod red. AG Iashchuk, RM Zainullina, AV Maslennikova, et al. Moscow: Pervaia tipografiia, 2018; p. 84 (in Russian).
7. Ziganshin AM, Mulykov AR. Immunopathological mechanisms in sepsis of viral etiology in COVID-19. Siberian Medical Review. 2021;6:35-43 (in Russian).
DOI:10.20333/25000136-2021-6-35-43
8. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res: Clin Obstet Gynaecol. 2018;47:14-26. DOI:10.1016/j.bpobgyn.2017.08.006
9. Keiffer TR, Soorya S, Sapp MJ. Recent Advances in Our Understanding of the Infectious Entry Pathway of Human Papillomavirus Type 16. Microorganisms. 2021;9(10):2076. DOI:10.3390/microorganisms9102076
10. Huber B, Schellenbacher C, Shafti-Keramat S, et al. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One. 2017;12(1):e0169533. DOI:10.1371/journal.pone.0169533
11. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864-78. DOI:10.20892/j.issn.2095-3941.2020.0370
12. Tekalegn Y, Sahiledengle B, Woldeyohannes D, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Womens Health (London). 2022;18:17455065221075904. DOI:10.1177/17455065221075904
13. Sadri Nahand J, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer. 2020;146(2):305-20. DOI:10.1002/ijc.32688
14. Barr AR, Cooper S, Heldt FS, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8:14728. DOI:10.1038/ncomms14728
15. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10:3116. DOI:10.3389/fmicb.2019.03116
16. Korolenkova LI, Zavolskaya ZHA, Leshkina GV. New opportunities of molecular testing in cervical screening and early diagnosis of cin and cervical cancer (based on the 2020 clinical guidelines of the RF Ministry of Healthcare “Cervical intraepithelial neoplasia, erosion and ectropion“). Medical Opponent. 2020;3(11):12-8 (in Russian).
17. Kojima Y, Otsuki N, Kubo M, et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells. Cancer Gene Ther. 2018;25(9-10):274-83. DOI:10.1038/s41417-018-0024-3
18. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203. DOI:10.1016/S2214-109X(19)30482-6
19. Zhen S, Lu J, Liu YH, et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout. Cancer Gene Ther. 2020;27(3-4):168-78. DOI:10.1038/s41417-019-0131-9
20. Bienvenu E, Mukanyangezi MF, Rulisa S, et al. Changes in the Proteome in the Development of Chronic Human Papillomavirus Infection-A Prospective Study in HIV Positive and HIV Negative Rwandan Women. Cancers (Basel). 2021;13(23):5983. DOI:10.3390/cancers13235983
21. Smalley Rumfield C, Pellom ST, Morillon Ii YM, et al. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer. 2020;8(1):e000612. DOI:10.1136/jitc-2020-000612
22. Sundström K, Elfström KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med. 2020;17(1):e1003035. DOI:10.1371/journal.pmed.1003035
23. Schlecht NF, Masika M, Diaz A, et al. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Network Open. 2019;2(10):e1914031. DOI:10.1001/jamanetworkopen.2019.14031
24. Saadeh K, Park I, Gargano JW, et al. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2020;38(1):39-45. DOI:10.1016/j.vaccine.2019.09.103
25. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Ann Intern Med. 2020;172(1):22-9. DOI:10.7326/M19-1182
26. Sonawane K, Suk R, Chiao EY, et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167(10):714-24. DOI:10.7326/M17-1363
27. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020;8(3):391. DOI:10.3390/vaccines8030391
28. Huber B, Wang JW, Roden RBS, Kirnbauer R. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. J Clin Med. 2021;10(5):1044. DOI:10.3390/jcm10051044
29. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9(12):1413. DOI:10.3390/vaccines9121413
30. Rosalik K, Tarney C, Han J. Human Papilloma Virus Vaccination. Viruses. 2021;13(6):1091. DOI:10.3390/v13061091
31. Wilkin TJ, Chen H, Cespedes MS, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. DOI:10.1093/cid/ciy274
32. Markowitz LE, Drolet M, Perez N, et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018;36(32 Pt A):4806-15. DOI:10.1016/j.vaccine.2018.01.057
33. Barnabas RV, Brown ER, Onono M, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials. 2021;22(1):661. DOI:10.1186/s13063-021-05608-8
34. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-90. DOI:10.1016/S0140-6736(20)30068-4
Авторы
А.М. Зиганшин*1, С.В. Кейдар2, Р.Ш. Халитова1, А.Р. Мулюков1, Э.Н. Мухамедьярова1
1 ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России, Уфа, Россия;
2 Государственный медицинский центр им. Эдит Вольфсон, Холон, Израиль
*zigaidar@yandex.ru
1 Bashkir State Medical University, Ufa, Russia;
2 Edith Wolfson Medical Center, Holon, Israel
*zigaidar@yandex.ru
1 ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России, Уфа, Россия;
2 Государственный медицинский центр им. Эдит Вольфсон, Холон, Израиль
*zigaidar@yandex.ru
________________________________________________
1 Bashkir State Medical University, Ufa, Russia;
2 Edith Wolfson Medical Center, Holon, Israel
*zigaidar@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.